NRXP
NRX Pharmaceuticals Inc (NRXP)
Healthcare • NASDAQ • $3.08+0.65%
- Symbol
- NRXP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.08
- Daily Change
- +0.65%
- Market Cap
- $101.85M
- Trailing P/E
- N/A
- Forward P/E
- 6.16
- 52W High
- $3.84
- 52W Low
- $1.62
- Analyst Target
- $38.25
- Dividend Yield
- N/A
- Beta
- 2.02
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression an…
Company websiteResearch NRXP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.